文献速递眼底病与葡萄膜炎

玻璃体切除术后无滴眼液方案:玻璃体内去赋形剂曲安奈德与莫西沙星的安全性和有效性

Dropless Pars Plana Vitrectomy Using Intravitreal Decanted Triamcinolone and Moxifloxacin: Safety and Efficacy.
PubMed 文献 · Retina · 2026-07-30

该回顾性研究纳入172只眼,比较玻璃体切除术(PPV)结束时玻璃体内注射去赋形剂曲安奈德(5 mg)和莫西沙星(500 μg)的无滴眼液方案与术后局部滴眼治疗。结果显示无滴眼液组前房炎症更轻、中央亚域厚度更低、黄斑囊样水肿(CME)发生率更低,最佳矫正视力(BCVA)改善更明显,眼压无差异,无眼内炎发生。

要点

  • PPV术毕玻璃体内注射去赋形剂曲安奈德5 mg和莫西沙星500 μg可替代术后局部滴眼治疗。
  • 无滴眼液组第2周和第3个月前房炎症显著轻于局部治疗组(P=0.0008,P=0.0223)。
  • 无滴眼液组CME发生率降低(P<0.001),BCVA改善更明显,眼压无差异,无眼内炎。

核心结论

  • PPV结束时玻璃体内注射去赋形剂曲安奈德和莫西沙星的无滴眼液方案安全有效,可减少术后炎症和CME并改善视力。

主要发现

  • 无滴眼液组第2周(P=0.0008)和第3个月(P=0.0223)前房炎症显著少于对照组。
  • 无滴眼液组平均CST在第2周(P=0.001)、第3个月(P=0.0009)和第6个月(P=0.012)更低。
  • 无滴眼液组CME发生率降低(P<0.001)。
  • 无滴眼液组BCVA改善更明显:第2周+15 vs -2.5 ETDRS字母(P=0.0003),第3个月+25 vs +9.5字母(P=0.002),第6个月+20 vs +8字母(P=0.01)。
  • 两组眼压相似,无眼内炎发生,ERM亚组结果一致。

关键数值与推荐

  • 无滴眼液方案:玻璃体内去赋形剂曲安奈德5 mg和莫西沙星500 μg。
  • 对照组局部用药:莫西沙星0.5%和醋酸泼尼松龙1%。

临床怎么用

  • PPV术毕可考虑玻璃体内注射去赋形剂曲安奈德和莫西沙星的无滴眼液方案替代术后局部滴眼治疗。

局限性

  • 回顾性研究设计,非随机分组,对照组来自前6个月手术患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of a dropless regimen using intravitreal decanted triamcinolone acetonide and moxifloxacin at the conclusion of pars plana vitrectomy (PPV), compared with standard postoperative topical therapy. METHODS: This retrospective study included consecutive patients undergoing PPV at a tertiary retina center. The dropless cohort (May-October 2025) received intravitreal decanted triamcinolone (5 mg) and moxifloxacin (500 μg). The control cohort, operated during the preceding 6 months, received topical moxifloxacin 0.5% and prednisolone acetate 1%. Outcomes included intraocular inflammation, intraocular pressure (IOP), central subfield thickness (CST), cystoid macular edema (CME), and best-corrected visual acuity (BCVA). A prespecified subgroup analysis was performed for epiretinal membrane (ERM). RESULTS: 172 eyes were included (87 dropless, 85 topical). The dropless group demonstrated significantly less anterior chamber inflammation at week 2 (P = 0.0008) and at month 3 (P = 0.0223). Mean CST was lower at week 2 (P = 0.001), month 3 (P = 0.0009), and month 6 (P = 0.012). CME incidence was reduced (P < 0.001). BCVA improvement was greater in the dropless group at week 2 (+15 vs -2.5 ETDRS letters; P = 0.0003), month 3 (+25 vs +9.5 letters; P = 0.002), and month 6 (+20 vs +8 letters; P = 0.01). IOP was similar between groups, and no endophthalmitis occurred. Findings were consistent in the ERM subgroup. CONCLUSION: A dropless intravitreal regimen at the conclusion of PPV can be a safe and effective alternative to topical therapy, with reduced postoperative inflammation and CME and improved visual outcomes.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Ali AL, Vail D, Morsy MS, et al. Dropless Pars Plana Vitrectomy Using Intravitreal Decanted Triamcinolone and Moxifloxacin: Safety and Efficacy. Retina. 2026. PMID: 42530451. doi:10.1097/IAE.0000000000004947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。